<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02154477</url>
  </required_header>
  <id_info>
    <org_study_id>L14-075</org_study_id>
    <nct_id>NCT02154477</nct_id>
  </id_info>
  <brief_title>Effect of Intranasal Insulin on LH Concentrations in Man</brief_title>
  <official_title>Effect of Intranasal Insulin on LH Concentrations in Man</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Texas Tech University Health Sciences Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Texas Tech University Health Sciences Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Over the last few years, studies have shown that men with type 2 diabetes sometimes develop a
      condition called hypogonadotrophic hypogonadism (HH). People with this condition produce
      little or no sex hormones. Obesity and metabolic syndrome are also associated with HH.
      Research suggests that insulin in the brain may benefit the glands that release these
      hormones. During this study, subjects will spray a small amount of insulin into their
      nose.This will increase insulin concentrations in the brain. The purpose of this study is to
      find out the effect of one dose of intranasal insulin on release of LH (a sex hormone) in
      obese diabetic men with HH.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Studies over the last few years have clearly established that at least 25% of men with type 2
      diabetes have subnormal free testosterone (T) concentrations in association with
      inappropriately low leutinizing hormone (LH) and FSH (follicle stimulating hormone)
      concentrations. These patients thus suffer from hypogonadotrophic hypogonadism (HH). Obesity
      and metabolic syndrome are also associated with HH. Animal studies and in vitro data have
      shown that insulin action and insulin responsiveness in the brain are necessary for the
      maintenance of the functional integrity of the hypothalamo-hypophyseal-gonadal axis. Insulin
      concentrations can be increased in the brain by delivering insulin intranasally with vianase
      device. The aim of this project is to study the effect of one dose of intranasal insulin on
      release of LH in obese diabetic men with HH. 15 obese men with type 2 diabetes and low free T
      along with normal LH concentrations will be recruited for the study. The study will be
      carried out at the clinical center of Texas Tech (Odessa campus). There will be two study
      visits, each comprising of blood tests every 15 minutes over 6 hours. 40 IU of intranasal
      insulin or saline will be given after a baseline period of blood sampling of 2 hours.
      Student's t-test will be used to compare the change in LH concentrations after intranasal
      saline or insulin.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 2014</start_date>
  <completion_date type="Actual">December 2017</completion_date>
  <primary_completion_date type="Actual">December 2017</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>LH</measure>
    <time_frame>4 hours</time_frame>
    <description>Luteinizing hormone (LH) concentrations after intranasal insulin as compared to placebo (intranasal saline). This endpoint was measured in both arms</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Hypogonadotropic Hypogonadism</condition>
  <arm_group>
    <arm_group_label>diabetes</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>All patient will receive insulin at one visit and saline at another visit</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>All patient will receive insulin at one visit and saline at another visit</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>intranasal insulin</intervention_name>
    <description>insulin</description>
    <arm_group_label>control</arm_group_label>
    <arm_group_label>diabetes</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo (intranasal saline)</intervention_name>
    <description>saline</description>
    <arm_group_label>control</arm_group_label>
    <arm_group_label>diabetes</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males age 18 to 75 years

          -  Obesity (BMI ≥30 kg/m2)

          -  Type 2 diabetes

          -  Hypogonadotropic hypogonadism defined as calculated free testosterone concentrations
             below 7 ng/dl along with normal or low LH concentrations

        Exclusion Criteria:

          -  HbA1c&gt;8.5%

          -  Use of preprandial insulin therapy

          -  Use of testosterone currently or in the past 4 months

          -  Use of over the counter health supplements which contain androgens

          -  Use of corticosteroids or narcotics in the past 3 months

          -  Coronary event or procedure(myocardial infarction, unstable angina, coronary artery
             bypass, surgery or coronary angioplasty) in the previous twelve weeks

          -  Type I Diabetes

          -  Currently suffering from foot ulcer, significant periodontal disease or any other
             chronic infectious or inflammatory condition

          -  Hepatic disease (transaminase &gt; 3 times normal) or cirrhosis

          -  Renal impairment (defined as glomerular filtration rate&lt;30)

          -  HIV or Hepatitis C positive status

          -  Any other life-threatening, non-cardiac disease

          -  History of untreated severe obstructive sleep apnea(defined as apnea-hypopnea index
             ≥30)

          -  currently suffering from symptomatic depression, with or without treatment

          -  Use of an investigational agent or therapeutic regimen within 30 days of study

          -  Participation in any other concurrent clinical trial

          -  Pituitary tumor/damage/ other trophic hormone deficiency
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sandeep Dhindsa, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>TTUHSC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>TTTUHSC-Permian Basin</name>
      <address>
        <city>Odessa</city>
        <state>Texas</state>
        <zip>79763</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Dhindsa S, Chemitiganti R, Ghanim H, Santiago E, Haider A, Chaar N, Mok M, McKee A, Dandona P. Intranasal Insulin Administration Does Not Affect LH Concentrations in Men with Diabetes. Int J Endocrinol. 2018 Oct 31;2018:6170154. doi: 10.1155/2018/6170154. eCollection 2018.</citation>
    <PMID>30515210</PMID>
  </results_reference>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>May 30, 2014</study_first_submitted>
  <study_first_submitted_qc>June 2, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 3, 2014</study_first_posted>
  <results_first_submitted>January 15, 2019</results_first_submitted>
  <results_first_submitted_qc>July 23, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">August 13, 2019</results_first_posted>
  <last_update_submitted>July 23, 2019</last_update_submitted>
  <last_update_submitted_qc>July 23, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 13, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>hypogonadotropic hypogonadism</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypogonadism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 29, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/77/NCT02154477/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Control</title>
          <description>lean healthy men, randomized to receive saline or insulin at first visit and the alternate treatment at second visit</description>
        </group>
        <group group_id="P2">
          <title>Diabetes</title>
          <description>men with diabetes, randomized to receive saline or insulin at first visit and the alternate treatment at second visit</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Diabetes</title>
          <description>All patients will be randomized to receive either insulin or saline at first visit and alternate treatment at the second visit
intranasal insulin
placebo (intranasal saline)</description>
        </group>
        <group group_id="B2">
          <title>Control</title>
          <description>All control subjects will be randomized to receive either insulin or saline at first visit and alternate treatment at the second visit
intranasal insulin
placebo (intranasal saline)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="14"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63" spread="7"/>
                    <measurement group_id="B2" value="30" spread="9"/>
                    <measurement group_id="B3" value="48" spread="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>LH</title>
        <description>Luteinizing hormone (LH) concentrations after intranasal insulin as compared to placebo (intranasal saline). This endpoint was measured in both arms</description>
        <time_frame>4 hours</time_frame>
        <population>diabetes</population>
        <group_list>
          <group group_id="O1">
            <title>Diabetes</title>
            <description>All patient will receive insulin at one visit and saline at another visit
intranasal insulin
placebo (intranasal saline)</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>lean healthy men. All men will receive insulin at one visit and saline at the other.</description>
          </group>
        </group_list>
        <measure>
          <title>LH</title>
          <description>Luteinizing hormone (LH) concentrations after intranasal insulin as compared to placebo (intranasal saline). This endpoint was measured in both arms</description>
          <population>diabetes</population>
          <units>IU/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.7" spread="3"/>
                    <measurement group_id="O2" value="3.3" spread="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>post-intervention saline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.9" spread="4.3"/>
                    <measurement group_id="O2" value="3.8" spread="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>post-intervention insulin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8" spread="3.4"/>
                    <measurement group_id="O2" value="3.4" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>4 hours</time_frame>
      <desc>hypoglycemia</desc>
      <group_list>
        <group group_id="E1">
          <title>Diabetes</title>
          <description>All diabetes patients were randomized to receive either insulin or saline at one visit and the alternate treatment at the second visit.
intranasal insulin
placebo (intranasal saline)</description>
        </group>
        <group group_id="E2">
          <title>Control</title>
          <description>All control subjects were randomized to receive either insulin or saline at one visit and the alternate treatment at the second visit.
intranasal insulin
placebo (intranasal saline)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>sandeep dhindsa</name_or_title>
      <organization>SLU</organization>
      <phone>314-977-4911</phone>
      <email>dhindsa@slu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

